Selegiline


Selective irreversible MAO-B inhibitor

A propargyl phenethylamine MAO-B inhibitor used in Parkinson disease and at higher doses in depression via MAO-A engagement.

Abstract

Selegiline ((R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine; CAS 14611-51-9; molecular formula C13H17N; molecular weight 187.28) is an irreversible propargyl-substituted MAO-B inhibitor developed by Joseph Knoll in Hungary in the 1960s. Metabolites include amphetamine and methamphetamine, contributing to subjective alertness and complicating drug screening. Used as a reference MAO-B selective inhibitor in Parkinson research and as a transdermal MAOI in depression studies.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph